ArticleThoracic cancer2024

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.

Yuki Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.